Galactosemia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The cost-effectiveness of the therapy of [[galactosemia]] has primarily been studied with respect to the [[screening]] program for the [[disease]] and the benefits reaped from it. | |||
==Cost-Effectiveness of Therapy== | ==Cost-Effectiveness of Therapy== | ||
The [[screening]] cost of [[galactosemia]] is less than the benefits i.e. QALYs achieved through [[screening]], thereby making its implementation cost-effective. Moreover, decreasing the [[false-positives]], using [[healthcare]] information systems and economical [[diagnostic]] techniques, establishing a centralized laboratory and combining with other screening programs will help in further reducing the financial burden. | The [[screening]] cost of [[galactosemia]] is less than the benefits i.e. QALYs achieved through [[screening]], thereby making its implementation cost-effective<ref name="pmid28451536">{{cite journal| author=Hatam N, Askarian M, Shirvani S, Siavashi E| title=Neonatal Screening: Cost-utility Analysis for Galactosemia. | journal=Iran J Public Health | year= 2017 | volume= 46 | issue= 1 | pages= 112-119 | pmid=28451536 | doi= | pmc=5401919 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28451536 }} </ref>. Moreover, decreasing the [[false-positives]] <ref name="pmid16735255">{{cite journal| author=Carroll AE, Downs SM| title=Comprehensive cost-utility analysis of newborn screening strategies. | journal=Pediatrics | year= 2006 | volume= 117 | issue= 5 Pt 2 | pages= S287-95 | pmid=16735255 | doi=10.1542/peds.2005-2633H | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16735255 }} </ref>, using [[healthcare]] information systems<ref name="pmid20703906">{{cite journal| author=Hsieh SH, Hsieh SL, Chien YH, Weng YC, Hsu KP, Chen CH | display-authors=etal| title=Newborn screening healthcare information system based on service-oriented architecture. | journal=J Med Syst | year= 2010 | volume= 34 | issue= 4 | pages= 519-30 | pmid=20703906 | doi=10.1007/s10916-009-9265-x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20703906 }} </ref> and economical [[diagnostic]] techniques, establishing a centralized laboratory <ref name="pmid22795865">{{cite journal| author=Lund AM, Hougaard DM, Simonsen H, Andresen BS, Christensen M, Dunø M | display-authors=etal| title=Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening. | journal=Mol Genet Metab | year= 2012 | volume= 107 | issue= 3 | pages= 281-93 | pmid=22795865 | doi=10.1016/j.ymgme.2012.06.006 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22795865 }} </ref> and combining with other screening programs <ref name="pmid19904445">{{cite journal| author=Padilla CD, Lam ST| title=Issues on universal screening for galactosemia. | journal=Ann Acad Med Singap | year= 2008 | volume= 37 | issue= 12 Suppl | pages= 39-3 | pmid=19904445 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19904445 }} </ref> will help in further reducing the financial burden. The [[efficiency]] of the [[neonatal]] [[screening]] policy is also inversely related to the prevailing interest rate in the economy<ref name="pmid19418240">{{cite journal| author=Camelo JS, Fernandes MI, Maciel LM, Scrideli CA, Santos JL, Camargo AS | display-authors=etal| title=Galactosaemia in a Brazilian population: high incidence and cost-benefit analysis. | journal=J Inherit Metab Dis | year= 2009 | volume= 32 Suppl 1 | issue= | pages= S141-9 | pmid=19418240 | doi=10.1007/s10545-009-1112-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19418240 }} </ref>. | ||
==References== | ==References== | ||
Latest revision as of 22:38, 5 July 2022
|
Galactosemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Galactosemia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Galactosemia cost-effectiveness of therapy |
|
Risk calculators and risk factors for Galactosemia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sujaya Chattopadhyay, M.D.[2]
Overview
The cost-effectiveness of the therapy of galactosemia has primarily been studied with respect to the screening program for the disease and the benefits reaped from it.
Cost-Effectiveness of Therapy
The screening cost of galactosemia is less than the benefits i.e. QALYs achieved through screening, thereby making its implementation cost-effective[1]. Moreover, decreasing the false-positives [2], using healthcare information systems[3] and economical diagnostic techniques, establishing a centralized laboratory [4] and combining with other screening programs [5] will help in further reducing the financial burden. The efficiency of the neonatal screening policy is also inversely related to the prevailing interest rate in the economy[6].
References
- ↑ Hatam N, Askarian M, Shirvani S, Siavashi E (2017). "Neonatal Screening: Cost-utility Analysis for Galactosemia". Iran J Public Health. 46 (1): 112–119. PMC 5401919. PMID 28451536.
- ↑ Carroll AE, Downs SM (2006). "Comprehensive cost-utility analysis of newborn screening strategies". Pediatrics. 117 (5 Pt 2): S287–95. doi:10.1542/peds.2005-2633H. PMID 16735255.
- ↑ Hsieh SH, Hsieh SL, Chien YH, Weng YC, Hsu KP, Chen CH; et al. (2010). "Newborn screening healthcare information system based on service-oriented architecture". J Med Syst. 34 (4): 519–30. doi:10.1007/s10916-009-9265-x. PMID 20703906.
- ↑ Lund AM, Hougaard DM, Simonsen H, Andresen BS, Christensen M, Dunø M; et al. (2012). "Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening". Mol Genet Metab. 107 (3): 281–93. doi:10.1016/j.ymgme.2012.06.006. PMID 22795865.
- ↑ Padilla CD, Lam ST (2008). "Issues on universal screening for galactosemia". Ann Acad Med Singap. 37 (12 Suppl): 39–3. PMID 19904445.
- ↑ Camelo JS, Fernandes MI, Maciel LM, Scrideli CA, Santos JL, Camargo AS; et al. (2009). "Galactosaemia in a Brazilian population: high incidence and cost-benefit analysis". J Inherit Metab Dis. 32 Suppl 1: S141–9. doi:10.1007/s10545-009-1112-1. PMID 19418240.